Teladoc Health (TDOC) Stock Price, News & Analysis

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TDOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TDOC, but not buy additional shares or sell existing shares.
View TDOC analyst ratings or view top-rated stocks.

13 equities research analysts have issued 12 month target prices for Teladoc Health's stock. Their TDOC share price targets range from $17.00 to $29.00. On average, they predict the company's share price to reach $22.23 in the next twelve months. This suggests a possible upside of 66.8% from the stock's current price.
View analysts price targets for TDOC or view top-rated stocks among Wall Street analysts.

Teladoc Health's stock was trading at $21.55 at the beginning of the year. Since then, TDOC shares have decreased by 38.1% and is now trading at $13.33.
View the best growth stocks for 2024 here.

Teladoc Health saw a increase in short interest in April. As of April 15th, there was short interest totaling 26,810,000 shares, an increase of 28.4% from the March 31st total of 20,880,000 shares. Based on an average daily volume of 4,860,000 shares, the days-to-cover ratio is currently 5.5 days.
View Teladoc Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our TDOC earnings forecast.

Teladoc Health, Inc. (NYSE:TDOC) released its earnings results on Tuesday, February, 20th. The health services provider reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.05. The health services provider earned $660.50 million during the quarter, compared to the consensus estimate of $670.79 million. Teladoc Health had a negative trailing twelve-month return on equity of 9.22% and a negative net margin of 8.47%. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) earnings per share.

ETFs with the largest weight of Teladoc Health (NYSE:TDOC) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), ARK Innovation ETF (ARKK), Fidelity Digital Health ETF (FDHT), iShares Virtual Work and Life Multisector ETF (IWFH), ARK Next Generation Internation ETF (ARKW), SoFi Be Your Own Boss ETF (BYOB) and SoFi Be Your Own Boss ETF (GIGE).

Teladoc Health updated its second quarter 2024 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of -0.450--0.350 for the period, compared to the consensus estimate of -0.300. The company issued revenue guidance of $635.0 million-$660.0 million, compared to the consensus revenue estimate of $662.6 million.

106 employees have rated Teladoc Health Chief Executive Officer Jason Gorevic on Glassdoor.com. Jason Gorevic has an approval rating of 95% among the company's employees. This puts Jason Gorevic in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Block (SQ), Shopify (SHOP), DocuSign (DOCU), Salesforce (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

Teladoc Health (TDOC) raised $112 million in an initial public offering on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.24%), Simplex Trading LLC (0.00%), IMC Chicago LLC (0.00%), Banque Cantonale Vaudoise (0.06%), Allspring Global Investments Holdings LLC (0.01%) and Counterpoint Mutual Funds LLC (0.01%). Insiders that own company stock include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Claus Torp Jensen, Daniel Trencher, David Travers, David William Sides, Jason N Gorevic, Karen L Daniel, Laizer Kornwasser, Mala Murthy, Michael Willem Waters, Nikolaos P Nanis, Richard J Napolitano, Sandra L Fenwick, Stephany Verstraete and Vidya Raman-Tangella.
View institutional ownership trends.

Shares of TDOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.